Stories
Parexel Expects Biotech Funding Recovery to Fuel Growth as India Emerges as a Key Hub
- •Parexel is counting on a recovery in biotech funding to drive future growth after a prolonged post-pandemic slowdown.
- •Biotechnology accounts for approximately 56 percent of Parexel's business and remains a major growth driver.
- •India has become a central strategic hub for Parexel, currently housing over 6,200 employees and functioning as a vital global capability centre.
- •Parexel expects its workforce in India to exceed 8,000 employees by 2030 amid rapid regional expansion.
- •Clinical trial activity in India is rising due to regulatory reforms, with Indian biopharma increasingly investing in innovative therapies and biosimilars.
Key Questions Answered
Parexel is driving its next phase of growth as fresh capital flows back into the biotech sector, where biotech accounts for about 56 percent of the company's business and yields high single-digit to double-digit growth. Chief Operating Officer Rob Goodwin noted that companies are reviving development pipelines with stronger assets and a higher probability of regulatory success.
India has become central to Parexel's operations, currently housing more than 6,200 employees—about a third of the company's global workforce—and serving as a strategic delivery centre for global clinical research programmes. Managing Director Sanjay Vyas stated that the workforce in India is projected to expand to over 8,000 employees by 2030.
Clinical trial applications in India have surged from around 80 to over 200 in the past five years, supported by regulatory reforms and government initiatives. While biosimilars dominate the landscape, Indian biopharma firms are increasingly investing in innovative therapies, new chemical entities, and advanced areas like cell and gene therapy.
